Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: The PROGRESS trial

Hisatomi Arima, Craig Anderson, Teruo Omae, Lisheng Liu, Christophe Tzourio, Mark Woodward, Stephen MacMahon, Bruce Neal, Anthony Rodgers, John Chalmers

Research output: Contribution to journalArticle

Abstract

Objective: To assess the benefits of blood pressure (BP) lowering on vascular events separately for Asian and for Western participants with particular emphasis on stroke subtypes and cardiac outcomes. Methods: This is a subsidiary analysis of Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a randomized, placebo-controlled trial that established the benefits of BP lowering in 6105 patients with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, and indapamide for those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). Outcomes are total and cause-specific vascular outcomes. Results: The annual rates for total major vascular events were 4.2% in Asian and 5.2% in Western participants. Overall stroke rates were greater in Asian compared to Western participants with proportionally more lacunar infarctions and haemorrhagic strokes in Asians and more cardio-embolic infarctions and large artery infarctions in Western participants. Active treatment reduced BP by 10.3/4.6 mmHg in Asian, and by 8.1/3.6 mmHg in Western participants. Among Asian participants there was a 38% [95% confidence interval (CI) 23-49%] reduction in major vascular events compared to a 20% (95% CI 7-31%) reduction in Western participants (P homogeneity = 0.06). Similarly, there were higher relative risk reductions for all other outcomes among Asian participants, but this only reached statistical significance for heart failure and vascular death (P = 0.02 for each). The number needed to treat for major vascular events over 5 years was 15 (95% CI 10-26) in Asian compared to 28 (95% CI 17-94) in Western participants (P homogeneity = 0.09). Conclusions: BP lowering reduces the risk of major vascular events, with separately significant reductions, in both Asia and the West.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalJournal of hypertension
Volume28
Issue number2
DOIs
StatePublished - Feb 2010

Keywords

  • Asian
  • Blood pressure lowering
  • Indapamide
  • Major vascular events
  • Perindopril
  • Randomized controlled trials
  • Stroke subtypes
  • Western

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: The PROGRESS trial'. Together they form a unique fingerprint.

  • Cite this

    Arima, H., Anderson, C., Omae, T., Liu, L., Tzourio, C., Woodward, M., MacMahon, S., Neal, B., Rodgers, A., & Chalmers, J. (2010). Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: The PROGRESS trial. Journal of hypertension, 28(2), 395-400. https://doi.org/10.1097/HJH.0b013e328333b009